Melbourne Clinical Trials

IBS Study MAD Cohort

Inflammatory Bowel Disease (IBD) is an autoimmune condition (your immune system attacks your own body), that comes in two forms: Ulcerative Colitis (UC) and Crohn’s Disease (CD). These two conditions create dysfunction within the gastrointestinal tract and further impact the immune system.

9 nights
1 + 1 follow up call visits

Current medications for these conditions are not very effective and have significant side effects. The medication in this study is given as an oral tablet and has been found to reduce inflammation in the bowels. For the initial stage of research into this medication, we require healthy participants with no medical conditions. This is so we can look at how the body metabolises the medication. At a later stage, it is hoped the medication will go on to be tested in patients with IBD.

The trial has been approved by an independent ethics committee and you will be reimbursed for your time.

Call us on 1800 243 733 to discuss your eligibility today!

Eligibility

Biological Sex Healthy males or females
Age 18-59 years old
BMI 19-31 kg/m²
Body Weight 60 - 85 kg
Medical History Nothing significant
Smoking History Non-smokers (past 1 month)